Onset of immunity with Mycoplasma synoviae: comparison of the live attenuated vaccine MS-H (Vaxsafe MS) with its wild-type parent strain (86079/7NS)

Avian Diseases
Jillian F JonesAmir H Noormohammadi

Abstract

The onset of protective immunity with MS-H was determined through experimental challenge and compared with the parent strain 86079/7NS. MS-H vaccinates and 86079/7NS inoculates were challenged at 1, 2, 3, 4, 5, and 6 wk after vaccination, then examined 2 wk after challenge for signs of respiratory disease. Serologic results indicated that 100% of MS-H vaccinates had antibodies to MS by 3 wk after vaccination and 100% of 86079/7NS inoculates were positive by 2 wk after inoculation. From 3 wk after vaccination, MS-H vaccinates had a significantly lower incidence of air sac lesions and, from 4 wk after vaccination, a significantly lower air sac lesion severity. In 86079/7NS-inoculated birds, a significantly lower incidence of air sac lesions was observed from 1 wk after inoculation, and air sac lesion severity was significantly lower than the unvaccinated controls at 3 wk after inoculation. It would appear that, under the conditions of this experiment, protective immunity elicited by MS-H appeared at 4 wk after vaccination, slightly later than the appearance of serum antibody. Although the MS-H vaccine was slower to establish protective immunity than 86079/7NS, there was no significant difference between the two strains by 4 wk af...Continue Reading

References

Aug 1, 1987·Nihon juigaku zasshi. The Japanese journal of veterinary science·T NunoyaS Sannai
Dec 1, 1996·Revue Scientifique Et Technique·K G Whithear

❮ Previous
Next ❯

Methods Mentioned

BETA
RSA
enzyme-linked immunosorbent assay
ELISA

Related Concepts

Related Feeds

Angelman Syndrome

Angelman syndrome is a neurogenetic imprinting disorder caused by loss of the maternally inherited UBE3A gene and is characterized by generalized epilepsy, limited expressive speech, sleep dysfunction, and movement disorders. Here is the latest research.